Introduction
Heart failure, HFpEF, HF, overactive bladder disease
HEART FAILURE
Heart failure (HF) is a major public health burden that affects 2% to 3% of adults in high-income countries.Despite the growing incidence of HFpEF over the last 20 years, the few therapies proven to be effective thus far were mainly tested a posteriori (ie, in patients with symptomatic HF).In this context, activation of the cardiac βMedications that specifically activate the human β3AR, such as mirabegron, have recently been developed and marketed for clinical use in overactive bladder disease. Mirabegron had few cardiovascular effects in previous urologic studies.